BOULDER, Colo.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that it has been issued a notice of allowance by the United States Patent and Trademark Office (USPTO) for a patent titled “Micro-RNAs that Modulate Smooth Muscle Proliferation and Differentiation and Uses Thereof.” The patent covers methods of use in modulating miR-143, a microRNA demonstrated by scientists at miRagen and University of Texas (UT) Southwestern Medical Center to play a critical role in controlling smooth muscle cells at the site of vascular injury, which occurs in a variety of vascular disease states.
